AnGes Inc (JP:4563)
:4563
Top Page
AnGes
(4563)
Select Model
Select Model
Rating:47Neutral
Price Target:
¥59.00
▼(-6.35% Downside)
Action:UpgradedDate:02/18/26
The score is held down primarily by persistent losses and heavy ongoing cash burn despite improving revenue momentum. Technical signals are mixed with a weaker longer-term trend, and valuation is constrained by a negative P/E and no dividend support.
Positive Factors
Revenue Momentum
Sustained revenue acceleration indicates improving commercial traction or progress in monetizable programs, which can extend runway and validate R&D direction. Over 2–6 months this momentum supports funding options, partner interest, and a clearer path toward scaling operations.
Negative Factors
Heavy Cash Burn
Persistently negative operating and free cash flow erodes liquidity and forces reliance on external capital. Over the next several months this increases dilution or covenant risk, constrains investment pacing, and limits ability to self-fund pivotal trials or commercialization activities.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Momentum
Sustained revenue acceleration indicates improving commercial traction or progress in monetizable programs, which can extend runway and validate R&D direction. Over 2–6 months this momentum supports funding options, partner interest, and a clearer path toward scaling operations.
Read all positive factors
AnGes (4563) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥23.38B
Dividend YieldN/A
Average Volume (3M)3.22M
Price to Earnings (P/E)―
Beta (1Y)0.32
Revenue Growth56.75%
EPS Growth-97.56%
CountryJP
Employees55
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.81
Shares Outstanding396,326,540
10 Day Avg. Volume1,701,110
30 Day Avg. Volume3,216,076
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)7.04
Price to Sales (P/S)24.76
P/FCF Ratio-3.75
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
AnGes Business Overview & Revenue Model
Company Description
AnGes, Inc., a biopharmaceutical company, engages in the research and development of gene-based medical products. Its lead product is Hepatocyte Growth Factor (HGF) Plasmid, a gene therapy for the treatment of critical limb ischemia, a serious imp...
How the Company Makes Money
AnGes generates revenue primarily through the development and commercialization of its biotechnology products, which includes licensing agreements, product sales, and research collaborations. The company often partners with larger pharmaceutical c...
AnGes Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
16
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 710.98M | 874.12M | 643.00M | 152.99M | 67.06M | 64.15M |
| Gross Profit | 260.04M | 320.38M | 247.00M | 19.45M | -26.83M | 7.43M |
| EBITDA | -6.25B | -5.09B | -5.74B | -8.86B | -13.41B | -13.21B |
| Net Income | -28.59B | -5.12B | -28.13B | -7.44B | -14.71B | -13.68B |
Balance Sheet | ||||||
| Total Assets | 5.79B | 5.41B | 4.67B | 28.89B | 38.82B | 45.46B |
| Cash, Cash Equivalents and Short-Term Investments | 2.91B | 1.88B | 1.71B | 4.16B | 11.04B | 17.90B |
| Total Debt | 198.79M | 54.37M | 272.45M | 362.68M | 1.16B | 0.00 |
| Total Liabilities | 2.38B | 2.33B | 2.51B | 2.79B | 8.40B | 6.82B |
| Stockholders Equity | 3.40B | 3.08B | 2.16B | 26.10B | 30.43B | 38.63B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | -5.76B | -6.69B | -8.84B | -11.23B | -11.46B |
| Operating Cash Flow | 0.00 | -5.75B | -6.61B | -8.74B | -11.21B | -11.38B |
| Investing Cash Flow | 0.00 | 18.48M | -130.80M | -356.65M | -97.14M | -154.87M |
| Financing Cash Flow | 0.00 | 5.90B | 4.20B | 2.04B | 3.57B | 17.38B |
AnGes Technical Analysis
Neutral
63.00
Price Trends
58.54
Positive
61.89
Negative
70.09
Negative
Market Momentum
0.09
Negative
52.28
Neutral
44.44
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4563, the sentiment is Neutral. The current price of 63 is above the 20-day moving average (MA) of 57.80, above the 50-day MA of 58.54, and below the 200-day MA of 70.09, indicating a neutral trend. The MACD of 0.09 indicates Negative momentum. The RSI at 52.28 is Neutral, neither overbought nor oversold. The STOCH value of 44.44 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for JP:4563.
AnGes Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | ¥73.61B | -17.30 | ― | ― | -9.04% | 13.09% | |
52 Neutral | ¥137.27B | -8.84 | ― | 2.18% | -0.16% | -802.20% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | ¥24.57B | -34.16 | ― | ― | -5.65% | -469.19% | |
50 Neutral | ¥49.01B | -13.30 | ― | ― | -82.33% | 47.73% | |
48 Neutral | ¥92.67B | -5.96 | -19.31% | ― | -1.96% | -64.18% | |
47 Neutral | ¥23.38B | -4.22 | -184.71% | ― | 56.75% | -97.56% |
* Healthcare Sector Average
JP:4563
AnGes
59.00
-2.00
-3.28%
JP:4565
Sosei Group
1,024.00
272.00
36.17%
JP:4588
Oncolys BioPharma, Inc.
2,516.00
1,998.00
385.71%
JP:4593
Healios KK
363.00
127.00
53.81%
JP:4974
Takara Bio Inc.
1,140.00
369.00
47.86%
JP:7774
Japan Tissue Engineering Co., Ltd.
605.00
196.00
47.92%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.